India’s diabetes crisis fuels explosive demand for weight loss drugs like Mounjaro
India is grappling with a diabetes epidemic, with over 100 million people diagnosed and another 135 million at risk. The surge in cases has led to a boom in demand for weight loss drugs, with Mounjaro leading the market by value since its approval in March.
Mounjaro and Ozempic, originally developed for diabetes, have been approved for obesity treatment. Their popularity has soared, with Mounjaro recording over $11 million in sales in October alone. The drugs have shown remarkable results, with a 27-year-old financial trader, Shyamanthak Kiran, losing over 60 pounds in six months using Mounjaro. However, the high cost is a barrier for many. A monthly course can cost up to $250, equivalent to the average monthly salary in many parts of India. Some patients are concerned about side effects, while others are willing to use these drugs long-term. Rajendra Nath Dixit, a retired banker, switched to oral semaglutide Rybelsus, combined it with exercise and diet changes, and saw significant health improvements.
The rising demand for weight loss drugs in India has caught some doctors and officials off guard. As the diabetes epidemic continues to grow, so too will the need for effective and affordable treatment options.
